All Interventions

    GLP-1 Agonists

    Pharmaceuticals
    Metabolic Drugs

    Glucagon-like peptide-1 receptor agonists for weight loss, metabolic optimization, and emerging anti-aging applications.

    Evidence Summary

    9
    / 10Score
    Strong
    Strong RCT Evidence

    Robust RCT data for weight loss (15-20%) and diabetes. Cardiovascular benefits proven. Emerging evidence for NASH, addiction, and neurological conditions. Preclinical geroscience update (Sep 2026): in a peer-reviewed Nature study (Feng…Chen, 2 Sep 2026), semaglutide started at 20 months of age in female C57BL/6 mice extended median lifespan by ~12% (834 vs 742 days), improved endurance, spatial memory and glucose control, enhanced stem-cell regenerative capacity, and attenuated transcriptomic ageing hallmarks — recapitulating and in some domains exceeding matched calorie restriction. This is the first lifespan result for a GLP-1RA begun late in life. It is mouse-only, female-only and single-site; it does not establish a longevity effect in humans, where the only randomised ageing-biomarker signal to date is a ~9% slowing of PCGrimAge pace in a specific HIV-lipohypertrophy cohort (Nat Commun 2026). UPDATE (November 1, 2026): PEER-REVIEWED, POST HOC ANALYSIS OF A PHASE 3 RCT. A SELECT secondary analysis (Ostrominski et al., JAMA Cardiology 2026; summarized in JAMA Medical News, 30 Oct 2026) stratified >17,000 participants by a 31-item frailty index (about two-thirds frail by index; mean age ~62, ~3/4 male). Semaglutide's cardiovascular benefit was reported as consistent across frailty strata, with fewer adverse-event discontinuations in more frail participants, and the frailty index was more likely to improve and less likely to worsen than on placebo. The authors frame it as hypothesis-generating; it does not show preserved muscle strength or physical performance in phenotypic frailty, and SELECT excluded type 2 diabetes, class IV heart failure and end-stage kidney disease/dialysis. Stratum-specific hazard ratios were not available to verify. UPDATE (November 8, 2026): EARLY / COMMERCIAL SIGNAL - NOT PEER REVIEWED. At ARDD 2026 Lilly (tirzepatide; single-arm SURMOUNT-5 epigenetic sub-study, n=71 paired, 2 of 15 clocks significant) and Novo Nordisk (semaglutide; proteomic clocks, reported by press as roughly 2-3 years slower biological age, trial details and effect sizes not verified) presented unpublished aging-clock data. Both are company conference presentations; clock changes are not clinical outcomes and effect size varied widely by clock and organ. Treat as hypothesis-generating.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Mimics incretin hormone GLP-1, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through CNS effects.

    Who Is This For?

    Obesity, type 2 diabetes, metabolic syndrome, cardiovascular risk reduction. GI tolerance assessment.

    Protocol & Dosing

    Dose

    Semaglutide: 0.25mg weekly, titrate to 1-2.4mg. Tirzepatide: 2.5mg weekly, titrate to 5-15mg.

    Frequency

    Weekly

    Duration

    Ongoing with monitoring

    Protocol Summary

    Weekly subcutaneous injection (semaglutide, tirzepatide) or daily oral. Titrate slowly to target dose.

    Semaglutide vs. Orforglipron

    Two paths to GLP-1 receptor activation — injectable peptide vs. oral small molecule.

    SemaglutideOrforglipron
    Oral
    ClassGLP-1 receptor agonist (peptide)Non-peptide GLP-1 receptor agonist (small molecule)
    RouteSubcutaneous injectionOral capsule
    Typical dose0.25–2.4 mg weekly3 mg / 12 mg / 24 mg / 36 mg daily
    Food restrictionsNoneNone (no fasting required)
    Half-life~7 days~24 hours
    Common useWeight loss, T2D, cardiometabolicWeight loss, glycemic control, T2D
    StageFDA-approved (Ozempic / Wegovy)FDA-approved (Foundayo)

    Oral GLP-1 (Orforglipron) — physician-vetted

    Available in 3 mg and 12 mg capsules through BioXSciences, an independent third-party supplier.

    Educational comparison only — not medical advice. Use under qualified physician supervision.

    Interactions & Precautions

    Contraindications

    • Personal/family history of medullary thyroid cancer
    • MEN2 syndrome
    • Pancreatitis history
    • Gastroparesis

    Potential Risks

    • •GI side effects
    • •Muscle loss
    • •Thyroid concerns (theoretical)
    • •Cost

    Potential Side Effects

    Nausea
    Vomiting
    Diarrhea
    Constipation
    Muscle loss (if not addressed)

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Protein intake critical to preserve muscle. Slow titration reduces GI effects. Consider cycling. Tirzepatide may be more effective. Monitor for muscle loss. Sep 2026: the Nature late-life mouse lifespan result (Feng…Chen) strengthens the calorie-restriction-mimetic rationale but should not be cited to patients as evidence that semaglutide extends human lifespan. Weigh against sarcopenia risk in older adults; body-composition monitoring and resistance training remain the priority. Watch the UTMB Moody tirzepatide-vs-epigenetic-clock trial and SURMOUNT-MMO for human ageing/mortality endpoints. Updated November 1, 2026: Frailty-index status alone should not automatically preclude semaglutide in older adults with obesity and established CVD, per this post hoc analysis — but it is a deficit-accumulation index, not a physical-performance measure. In phenotypically frail or sarcopenic patients, lean-mass and function monitoring and resistance training remain the priority; caution is still warranted outside the SELECT population (diabetes, advanced heart failure, dialysis).
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $$$$

    Accessibility

    Prescription

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation